Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.

by Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S Kim, Ying Wang, Patrick G Gavin, Peter C Lucas, Ashok Srinivasan, Carmen J Allegra, Samuel A Jacobs, Soonmyung Paik, John C Schmitz, Katherine L Pogue-Geile
Published 2018-01-01

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ br...

by Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Published 2020-01-01

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

by Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Published 2019-12-01